EBQ:RE-LY: Difference between revisions
Ostermayer (talk | contribs) No edit summary |
Ostermayer (talk | contribs) (question and conclusion) |
||
| Line 15: | Line 15: | ||
}} | }} | ||
==Clinical Question== | ==Clinical Question== | ||
Is dabigatran (brand name Pradaxa) safe for use in patients with atrial fibrillation when compared to warfarin in terms of stroke and bleeding risks | |||
==Conclusion== | ==Conclusion== | ||
In comparison to warfarin in patients with atrial fibrillation, dabigatran given at a dose of 110 mg demonstrated similar stroke and lower bleeding rates. At 150 mg, dabigatran use was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. | |||
==Major Points== | ==Major Points== | ||
Revision as of 12:18, 25 November 2013
incomplete Journal Club Article
Connolly SJ, et al. "Dabigatran versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 2009. 361(12):1139-51.
PubMed Full text PDF
PubMed Full text PDF
Clinical Question
Is dabigatran (brand name Pradaxa) safe for use in patients with atrial fibrillation when compared to warfarin in terms of stroke and bleeding risks
Conclusion
In comparison to warfarin in patients with atrial fibrillation, dabigatran given at a dose of 110 mg demonstrated similar stroke and lower bleeding rates. At 150 mg, dabigatran use was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.